^
BIOMARKER:
KRAS G13D
i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
›
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
panitumumab Resistant: A2 - Guideline
|
panitumumab Resistant: A2 - Guideline
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
cetuximab Resistant: A2 - Guideline
|
cetuximab Resistant: A2 - Guideline
|
KRAS G13D
|
HCC
|
KRAS G13D
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G13D
|
NSCLC
|
KRAS G13D
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
RGX-202 Sensitive: C3 – Early Trials
|
RGX-202 Sensitive: C3 – Early Trials
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
|
KRAS G13D
|
NSCLC
|
KRAS G13D
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
LY3214996 Sensitive: D – Preclinical
|
LY3214996 Sensitive: D – Preclinical
|
KRAS G13D
|
Colon Cancer
|
KRAS G13D
|
Colon Cancer
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
MEN1611 Sensitive: D – Preclinical
|
MEN1611 Sensitive: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
BMS-754807 Resistant: D – Preclinical
|
BMS-754807 Resistant: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
cetuximab + vemurafenib Resistant: D – Preclinical
|
cetuximab + vemurafenib Resistant: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
sunitinib Resistant: D – Preclinical
|
sunitinib Resistant: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
trametinib + TPX-0005 Sensitive: D – Preclinical
|
trametinib + TPX-0005 Sensitive: D – Preclinical
|
KRAS G13D
|
CRC
|
KRAS G13D
|
CRC
|
P1446A-05 Sensitive: D – Preclinical
|
P1446A-05 Sensitive: D – Preclinical
|
KRAS G13D
|
Solid Tumor
|
KRAS G13D
|
Solid Tumor
|
MRTX849 Sensitive: D – Preclinical
|
MRTX849 Sensitive: D – Preclinical
|
KRAS G13D
|
Solid Tumor
|
KRAS G13D
|
Solid Tumor
|
sotorasib Resistant: D – Preclinical
|
sotorasib Resistant: D – Preclinical
|
KRAS G13D
|
Pancreatic Adenocarcinoma
|
KRAS G13D
|
Pancreatic Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
KRAS G13D
|
Colorectal Adenocarcinoma
|
KRAS G13D
|
Colorectal Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
